Platinum compounds 30 years after the introduction of cisplatin: Implications for the treatment of ovarian cancer

This publication has 54 references indexed in Scilit:

• How do real tumors become resistant to cisplatin?
  Cell Cycle, 2008
• Secondary BRCA1 Mutations in BRCA1-Mutated Ovarian Carcinomas with Platinum Resistance
  Cancer Research, 2008
• Tolerance and activity of oxaliplatin with protracted topotecan infusion in patients with previously treated ovarian cancer. A phase I study
  Gynecologic Oncology, 2008
• Secondary mutations as a mechanism of cisplatin resistance in BRCA2-mutated cancers
  Nature, 2008
• Somatic loss of BRCA1 and p53 in mice induces mammary tumors with features of human BRCA1 -mutated basal-like breast cancer
  Proceedings of the National Academy of Sciences, 2007
• Selective induction of chemotherapy resistance of mammary tumors in a conditional mouse model for hereditary breast cancer
  Proceedings of the National Academy of Sciences, 2007
• Oxaliplatin for the treatment of cisplatin-resistant cancer: A systematic review
  Cancer Treatment Reviews, 2007
• Second-line chemotherapy with pegylated liposomal doxorubicin and carboplatin is highly effective in patients with advanced ovarian cancer in late relapse: a GINECO phase II trial
  Annals of Oncology, 2006
• Ovarian cancer side population defines cells with stem cell-like characteristics and Mullerian Inhibiting Substance responsiveness
  Proceedings of the National Academy of Sciences, 2006
• Sequential single agents as first-line chemotherapy for ovarian cancer: a strategy derived from the results of GOG-132
  International Journal of Gynecological Cancer, 2003